Rational dosing of antibiotics in neonates should be based on pharmacokinetic (PK) parameters assessed in specific populations. PK studies in neonates are hampered by the limited total plasma volume, which restricts sample volume and sampling frequency. 30
Introduction 50
Successful drug therapy depends on the administration of the appropriate dose at the right dose interval, which implies an understanding of the drugs pharmacokinetic (PK) profile. This is particularly relevant in the treatment of neonatal and pediatric patients, considering potential variation in PK parameters due to an individuals developmental 55 stage or specific morbidity. Therefore, PK parameters should be assessed in the specific populations to which the drugs are given to prevent either undertreatment or unnecessary toxicity. Unfortunately, pharmacokinetic studies in neonates are complicated by the limited amount of biological material (e.g. blood, plasma) available, which poses restrictions on sampling frequency and sample volume (20) . Moreover, the 60 number of patients participating in these studies is often low, especially when studying patients of narrowly defined age groups, with specific (co-) morbidity or during treatment with extracorporeal techniques. Ideally, analytes of interest should be quantitated simultaneously in as little sample as possible. This limits the burden on individual patients caused by sampling, while maintaining sufficient data points for 65 reliable data analysis.
For years, drugs have been quantified via high-performance liquid chromatography with ultraviolet detection (HPLC-UV). Many of the published bio-analytical methods require sample volumes of 250 µL or more (5, 8, 11, 13, 16) . Some are labor-intensive (5, 7, 11) or require long run-times (7, 11, 12) , potentially leading to poor reproducibility for 70 analytes that may decompose during analysis, such as certain β-lactam antibiotics.
Analytes had to be chromatographically separated from the interfering endogenous and exogenous matrix components, and often an elaborate sample preparation was necessary to reach sufficient selectivity and specificity. Co-eluting components would often
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on November 3, 2017 by guest http://aac.asm.org/ Downloaded from interfere due to low specificity of UV-detection. With the advent of mass spectrometry 75 (MS), selectivity greatly increased since specific analyte masses could be detected. This led to an even greater specificity when mass spectrometers were set up in sequence (tandem mass spectrometry, or MS/MS): now, not only a specific mass could be identified, but a specific fragmentation pattern could be monitored to differentiate between analytes with the same mass. 80
Equipment capable of ultra-performance liquid chromatography mass spectrometry (UPLC-MS/MS) has recently become available. With a smaller particle size and higher operating pressures compared to regular HPLC, UPLC provides a shorter runtime and sharper peak shape, which improves sensitivity and reduces potential interference by matrix components (6, 10, 17) . UPLC combined with tandem mass spectrometry should 85 therefore allow quantitative analysis of multiple analytes with minimal sample preparation and matrix effects.
Currently, clinical studies in the Sophia Children's Hospital include pharmacokinetic evaluations of multiple antibiotics in patients receiving extracorporeal membrane oxygenation (ECMO) treatment. In order to facilitate these studies, a simple and reliable 90 method was developed to simultaneously quantify amoxicillin, meropenem, cefazolin, cefotaxime, deacetylcefotaxime, ceftriaxone and vancomycin in 50 µL of plasma. In this manuscript, the method is presented, validation results are reported and method applicability is demonstrated with data from an ECMO-treated patient. (ii) Limit of quantification. The lower limit of quantification (LLOQ) was defined as the lowest concentration that could be quantified with accuracy and precision ± 20%, as calculated from chromatograms of 6 independent samples. 160 (iii) Standard curves. Curves consisting of eight points were calculated by linear or polynomial regression, each point consisting of independent triplicate measurements.
Best fit was selected after exploration of different regression models and weighting factors. medium QC samples (in duplicate) at a column temp of 40°C were compared to those observed at a column temp of 30°C; and (c) signal intensity of medium QC samples (in duplicate) was compared to that observed in medium QC samples that were diluted preprecipitation (1:9 with water) to see whether dilution improved analyte recovery .
(vi) Matrixeffects. Plasma and eluent components in the ionization chamber cause 180 batchspecific ion suppression or enhancement, leading to interpatient and intrapatient signal variability (4, 19) . These matrixeffects were evaluated in two ways. First, extracts of six batches of blank plasma were injected while analytes were continuously infused into the mass spectrometer. Ion traces were recorded for each compound over the entire runtime. Signal stability at the relevant retention time was visually assessed for each 185 analyte over the six batches of blank plasma. Second, matrixeffects were quantified as proposed by Matuszewski et al (14) . In short, chromatograms were recorded of plasma that was spiked pre-extraction, plasma spiked post-extraction and spiked aqueous eluent. In total, six batches of blank plasma were spiked with low and high decannulation. In total, 11 samples were taken extracorporeally from a pre-oxygenator access point during the 84 hr ECMO-run. After this period, the patient was successfully decannulated and transferred to the referring NICU on conventional ventilation. Plasmareported pharmacokinetic parameters using MW\Pharm software (MW\PHARM 3.58, Mediware, The Netherlands). Cefotaxime was modelled on a one-compartment model 220 derived from data in non-ECMO neonates (15) using iterative Bayesian fitting.
Amoxicillin was modelled on a one-compartment model derived from non-ECMO neonates (18) using iterative Bayesian fitting. Vancomycin was modelled on a twocompartment model derived from ECMO-neonates (1) using non-Bayesian fitting. were within 100 ± 20% and CV < 20%, respectively. See table 2 for intrarun accuracy and precision. Interrun accuracy and precision were similar, with accuracy and precision 245 of within 100 ± 15% and CV < 15% for all analytes.
Robustness. Reconstitution with water instead of 0.1% FA improved signal intensity of CFZ (+8%), DACT (+10%) and CRO (+300%); water had no effect on signal intensity of the other analytes. 24h degradation (autosampler, 5°C) however was considerably Matrixeffects. Visual inspection of chromatograms of plasma injected during Tinfusion revealed a signal loss of roughly 30-50% due to matrix components. Interplasmabatch variability appeared small and there were no sudden signal losses or peaks around the respective retention times. ME, RE and PE were similar for low and high QC-samples, see fig. 2 for the high QC samples. PE varied between 20% (VAN) and 260 75% (CRO) with notable ME and RE for each analyte. CRO was the only analyte with ion enhancement due to matrix components, as opposed to the ion suppression seen with the other analytes. ME and RE coefficients of variation over the six different plasma batches were under 10% for each analyte.
Sample stability. Analytes were stable for at least 2 months in water and plasma at -265 80°C. Maximum storage periods of aqueous solutions, plasma, wholeblood and extracts (table 3) are based on a maximum degradation of 10%. After three freeze-thawcycles (n=2 for both low and high QC concentrations), average remaining concentrations in extracts were at least 90% of the initial concentration, except for MEM (79%).
Measurement of plasma levels in a neonatal ECMO-patient. Plasma levels of CTX, 270
DACT, AMX and VAN were measured simultaneously in the 50 µL plasma samples and successfully fitted to the previously reported models. 
Discussion
We report the development of a fast UPLC-MS/MS method with an analytical 280 performance meeting FDA specifications. The required plasma volume is 50 µL, which is sufficient to allow reinjection. If the latter is not deemed necessary, the sample volume could probably even be reduced to 20 µL.
This method can be expanded for the quantification of other β-lactam antibiotics by scanning additional mass transitions. We have for instance tested ceftazidime and 285 cefuroxime with sufficient retention, signal intensity and peak shape. From the presented group of antibiotics, only CRO had a potentially problematic peakshape, but accuracy and precision were adequate. We tested an adjusted gradient, but were unsuccessful in removing CRO tailing while maintaining resolution between CTX and the CFZ-isotope peak. 290
Limited availability of a reference standard complicated a full validation with respect to DACT-quantitation. Considering the structural, chromatographic and mass spectrometric similarities between DACT and CTX, we assumed that their analytical performances would be similar and limited the validation procedure to the critical aspects of matrix effects and sample stability. Vancomycin clearance and volume of distribution were similar to those reported previously in ECMO-treated neonates (1), although clearance is higher in our patient.
With pharmacokinetic software, we were able to construct concentration-time curves 325 and calculate individual pharmacokinetic parameters for this neonate using existing models. The high sampling frequency during classic pharmacokinetic studies can be 
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